cbdMD is a small consumer wellness company that makes and sells hemp-derived cannabidiol products. Its core brand, cbdMD, sells CBD oils, gummies, capsules, soft-gels, and topicals targeting wellness use cases like sleep, stress, mood, and pain relief. The company also operates Paw CBD, a pet wellness line offering hemp-derived products for dogs and cats; Herbal Oasis, a hemp-derived THC-infused functional seltzer positioned as an alcohol alternative; and ATRx Labs, a functional mushroom and nootropic supplement line. cbdMD and Paw CBD drive the vast majority of revenue, while Oasis and ATRx are early-stage. cbdMD sells roughly 77% of its products DTC through its own websites and online marketplaces, with the remaining ~23% through wholesale — national and regional retailers, specialty health and pet stores, and international distributors. The DTC channel is the primary profit driver, with gross margins running around 62-66%, reflecting the DTC-heavy mix and ongoing SKU rationalization. Key economic levers include customer acquisition cost relative to DTC revenue and subscription and repeat purchase rates. Wholesale carries lower margins but provides brand visibility and incremental revenue. The Oasis beverage line is distributed through beer and alcohol networks and is currently dilutive to margins as cbdMD invests in scaling distribution. A notable regulatory risk is pending legislation that would cap THC content in hemp-derived consumables, potentially impacting the roughly 40-45% of cbdMD's revenue derived from full-spectrum SKUs.